Dry powder inhalation type pharmaceutical composition and preparation method thereof
By using amino acids, glycosides and other excipients in bedaquiline dry powder inhalation pharmaceutical compositions, the problem of long onset of traditional oral administration of bedaquiline is solved, and faster onset is achieved and better aerosol properties.
Patent Information
- Application Number
- CN202410637662.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-24
- Filing Date
- 2024-05-22
- Publication Date
- 2024-11-26
AI Technical Summary
As an anti-tuberculosis drug, bedaquiline has a long onset time, and how to provide dry powder inhaled pharmaceutical compositions to improve its onset time.
Using dry powder inhalation pharmaceutical compositions including bedaquiline or its pharmaceutically acceptable salts, using amino acids, polysaccharides, phospholipids, polylactic acid, polylactic acid copolymers, etc. as excipients, 50 nanometers are prepared by spray drying technology to 6 micron particles, adjust particle size and shape to improve aerosol properties.
It significantly improves the onset time of bedaquiline, increases the flight distance of particles and the proportion of lung partial cloth, improves the characteristics of aerosols, meets the needs of inhalation delivery, and reduces the onset time.
Smart Images

Figure CN119015264A_ABST
Abstract
Description
Technical Field
[0001] The present disclosure relates to a dry powder inhalation pharmaceutical composition and a preparation method thereof. Specifically, the present disclosure relates to a pharmaceutical composition comprising bedaquiline or a pharmaceutically acceptable salt thereof. Background Art
[0002] Bedaquiline (BED) is a diarylquinoline. Due to the properties of diarylquinoline, bedaquiline can be used as an anti-tuberculosis drug. However, bedaquiline is traditionally administered orally, and because bedaquiline needs to be absorbed through the gastrointestinal tract before entering the blood circulation, it takes a long time to take effect.
[0003] Therefore, a problem to be solved is how to provide a dry powder inhalation-type pharmaceutical composition containing bedaquiline to increase the onset time of bedaquiline. Summary of the invention
[0004] In one aspect of the present disclosure, a dry powder inhalation pharmaceutical composition is provided, comprising: an active ingredient and a first pharmaceutically acceptable excipient. The active ingredient comprises bedaquiline or a pharmaceutically acceptable salt thereof. The first pharmaceutically acceptable excipient comprises an amino acid, a polysaccharide, a phospholipid, polylactic acid, a polylactic acid copolymer, or a combination thereof.
[0005] In some embodiments, when the weight of the active ingredient and the first pharmaceutically acceptable excipient is 100%, the weight percentage of the active ingredient is 50% to 99%, and the weight percentage of the first pharmaceutically acceptable excipient is 1% to 50%.
[0006] In some embodiments, when the weight of the active ingredient and the first pharmaceutically acceptable excipient is 100%, the weight percentage of the amino acid is 1% to 20%.
[0007] In some embodiments, the amino acids include glycine, alanine, valine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, histidine, asparagine, glutamic acid, lysine, glutamine, methionine, arginine, serine, threonine, cysteine, proline, or a combination thereof.
[0008] In some embodiments, when the weight of the active ingredient and the first pharmaceutically acceptable excipient is 100%, the weight percentage of the polysaccharide is 1% to 20%.
[0009] In some embodiments, the polysaccharide comprises chitosan, a chitosan salt, or a combination thereof.
[0010] In some embodiments, when the weight of the active ingredient and the first pharmaceutically acceptable excipient is taken as 100%, the weight percentage of the phospholipid is 1% to 50%.
[0011] In some embodiments, the phospholipid comprises dipalmitoylphosphatidylcholine (DPPC), distearoyl phosphatidyl choline (DSPC), or a combination thereof.
[0012] In some embodiments, when the weight of the active ingredient and the first pharmaceutically acceptable excipient is 100%, the weight percentage of the polylactic acid is 1% to 50%.
[0013] In some embodiments, when the weight of the active ingredient and the first pharmaceutically acceptable excipient is 100%, the weight percentage of the polylactic acid copolymer is 1% to 50%.
[0014] In some embodiments, the polylactic acid copolymer comprises poly(lactic-co-glycolic acid) .
[0015] In some embodiments, the active ingredient and the first pharmaceutically acceptable excipient form microparticles having a particle size of 50 nanometers to 6 micrometers.
[0016] In some embodiments, the microparticles are in the shape of solid spheres, hollow spheres, solid polyhedrons, or a combination thereof.
[0017] In some embodiments, the pharmaceutical composition further includes a second pharmaceutically acceptable excipient that is different from the first pharmaceutically acceptable excipient.
[0018] In some embodiments, when the weight of the pharmaceutical composition is 100%, the weight percentage of the second pharmaceutically acceptable excipient is 70% to 99.995%.
[0019] In some embodiments, the second pharmaceutically acceptable excipient comprises lactose, mannitol, or a combination thereof.
[0020] Another aspect of the present disclosure provides a method for preparing a dry powder inhalation pharmaceutical composition, comprising: dissolving an active ingredient in a first solvent to form a first solution, wherein the active ingredient comprises bedaquiline or a pharmaceutically acceptable salt thereof; dissolving a first pharmaceutically acceptable excipient in a second solvent to form a second solution, wherein the first pharmaceutically acceptable excipient comprises an amino acid, a polysaccharide, a phospholipid, polylactic acid, a polylactic acid copolymer or a combination thereof; mixing the first solution and the second solution to form a mixed solution; and spray drying the mixed solution to form microparticles.
[0021] In some embodiments, the first solvent and the second solvent include organic solvents.
[0022] In some embodiments, when the weight of the mixed solution is 100%, the weight percentage of the active ingredient and the first pharmaceutically acceptable excipient is 0.5% to 3%.
[0023] In some embodiments, the weight ratio of the active ingredient to the first pharmaceutically acceptable excipient in the mixed solution is 1:1 to 199:1.
[0024] In some embodiments, spray drying the mixed liquor is performed at an outlet temperature of 35°C to 110°C.
[0025] In some embodiments, in the step of spray-drying the mixed solution, the ultrasonic atomization percentage of the mixed solution is 25% to 85%.
[0026] In some embodiments, the method further comprises mixing the microparticles with a second pharmaceutically acceptable excipient different from the first pharmaceutically acceptable excipient.
[0027] In some embodiments, the second pharmaceutically acceptable excipient comprises a first size population, a second size population, or a combination thereof, wherein the volume-based particle size distribution of the first size population is different from the volume-based particle size distribution of the second size population.
[0028] In some embodiments, the D50 particle size of the first size population is between 5 microns and 50 microns, and the D50 particle size of the second size population is between 30 microns and 125 microns.
[0029] In some embodiments, the method further comprises mixing the microparticles with a flavoring agent. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] The above and other objects, features, advantages and embodiments of the present disclosure may be more fully understood by reading the following detailed description of the embodiments with reference to the accompanying drawings.
[0031] Figure 1 The present invention is a flow chart showing a method for preparing a dry powder inhalable pharmaceutical composition according to some embodiments of the present disclosure.
[0032] Figure 2A as well as Figure 2B The electron microscope images of bedaquiline before spray drying and microparticles are shown respectively.
[0033] Figure 3A as well as Figure 3B The particles are shown in the electron microscope field. Figure 3AThe bedaquiline was mixed with dipalmitoyl phosphatidylcholine (DPPC) before spray drying. Figure 3B The bedaquiline was mixed with distearoyl phosphatidyl choline (DSPC) before spray drying.
[0034] Figure 4 The electron microscope image shows the microparticles in which bedaquiline was mixed with poly(lactic-co-glycolic acid, PLGA) before spray drying.
[0035] Figure 5 To illustrate the aerosol characteristics of the “BED only” group, the “BED+DSPC” group, and the “BED+DSPC+Lac” group detected using the Next Generation Impactor (NGI). DETAILED DESCRIPTION
[0036] In order to describe the present disclosure in detail and completely, the implementation and specific embodiments of the present disclosure are given with exemplary descriptions, but these are not the only forms of implementing or using the specific embodiments of the present disclosure. The embodiments disclosed herein can be combined or replaced with each other in an advantageous manner, and other embodiments can be added to an embodiment without further description. In the following description, many specific details will be described in detail so that the reader fully understands the following embodiments. However, the embodiments of the present disclosure can be put into practice without these specific details.
[0037] Although a series of operations or steps are described below to illustrate the method disclosed herein, the order of operations or steps should not be construed as limiting. For example, certain operations or steps can be performed in different orders and / or performed simultaneously with other steps. In addition, not all operations, steps and / or features shown are necessary to realize the embodiment of the present disclosure. In addition, each operation or step described herein may include multiple sub-steps or actions.
[0038] In this document, unless otherwise specified, "a", "an" and "the" may refer to a single or multiple. It should also be understood that "comprising", "including", "having" and similar terms in this document refer to the described features, regions, integers, steps, operations, elements and / or components, but do not exclude other features, regions, integers, steps, operations, elements, components and / or groups.
[0039] As used herein, "drug" or "active ingredient" refers to bedaquiline or a pharmaceutically acceptable salt thereof, including but not limited to salts, esters, complexes, chelates, caged compounds, racemates, or mirror image isomers.
[0040] As used herein, "pharmaceutically acceptable excipient" refers to a pharmaceutical additive that has no pharmacological activity and has various uses and functions and is used in a pharmaceutical composition.
[0041] The main purpose of the present disclosure is to provide a dry powder inhalable pharmaceutical composition with a smaller particle size and a specific shape, thereby improving the aerosol property (e.g., increasing the fine particle fraction (FPF)) of the pharmaceutical composition to meet the requirements of inhalation administration and reduce the onset time.
[0042] Please refer to Figure 1 , presents a flow chart of a method 100 for preparing a dry powder inhalation pharmaceutical composition in some embodiments of the present disclosure, including step S110, step S120, step S130, and step S140. It should be emphasized that by mixing the first pharmaceutically acceptable excipient and bedaquiline in the mixed solution, and then spray drying the mixed solution, the shape and particle size of the microparticles can be regulated, thereby improving the aerosol properties and onset time of the microparticles.
[0043] First, referring to step S110 , an active ingredient is dissolved in a first solvent to form a first solution, wherein the active ingredient includes bedaquiline or a pharmaceutically acceptable salt thereof.
[0044] In some embodiments, the first solution includes an organic solvent to easily dissolve the active ingredient, such as ethanol, methanol, dichloromethane, ethyl acetate, acetonitrile, acetone, or a combination thereof. In some other embodiments, the first solution includes water.
[0045] Referring to step S120 , a first pharmaceutically acceptable excipient is dissolved in a second solvent to form a second solution, wherein the first pharmaceutically acceptable excipient includes amino acids, polysaccharides, phospholipids, polylactic acid, polylactic acid copolymers or a combination thereof.
[0046] In some embodiments, the second solution includes an organic solvent to easily dissolve the active ingredient, such as ethanol, methanol, dichloromethane, ethyl acetate, acetonitrile, acetone, or a combination thereof. In some embodiments, the second solution is the same as the first solution.
[0047] In some embodiments, the amino acid comprises glycine, alanine, valine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, histidine, asparagine, glutamic acid, lysine, glutamine, methionine, arginine, serine, threonine, cysteine, proline or a combination thereof. In some embodiments, the polysaccharide comprises chitosan, chitosan salt or a combination thereof. In some embodiments, the phospholipid comprises dipalmitoylphosphatidylcholine (DPPC), distearoyl phosphatidylcholine (DSPC) or a combination thereof. In some embodiments, the polylactic acid copolymer comprises polylactic acid-glycolic acid (poly(lactic-co-glycolic acid, PLGA).
[0048] Referring to step S130 , the first solution and the second solution are mixed to form a mixed solution.
[0049] In some embodiments, when the weight of the mixed solution is 100%, the weight percentage of the active ingredient and the first pharmaceutically acceptable excipient is 0.5% to 3%, such as 0.5%, 1%, 1.5%, 2%, 2.5%, 3% or any value between any intervals of the above values. If the weight percentage is too low, the yield of spray drying is limited. If the weight percentage is too high, the mixed solution may be uneven and too viscous to be spray dried, resulting in limited efficiency of spray drying. In some embodiments, the weight ratio of the active ingredient to the first pharmaceutically acceptable excipient in the mixed solution is 1:1 to 199:1, for example, 1:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 100:1, 110:1, 120:1, 130:1, 140:1, 150:1, 160:1, 170:1, 180:1, 190:1, 199:1 or any value between any intervals of the above values. If the weight ratio is too low, the content of the active ingredient contained in the microparticles after spray drying is limited. If the weight ratio is too high, the aerosol properties are weakened because the microparticles are difficult to be regulated by the first pharmaceutically acceptable excipient.
[0050] Please refer to step S140, spray drying the mixed liquid to form microparticles.
[0051] In some embodiments, the spray drying of the mixed solution is performed at an outlet temperature of 35°C to 110°C, such as 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 110°C or any value between any intervals of the above values. If the outlet temperature is too low, the sprayed droplets are too large, the particle size of the spray-dried particles tends to be larger, and the shape of the spray-dried particles will be difficult to maintain in a spherical shape. If the outlet temperature is too high, the structure of the active ingredient or pharmaceutically acceptable excipient may change, affecting its function. In some embodiments, in the step of spray drying the mixed solution, the ultrasonic atomization percentage of the mixed solution is 25% to 85%, such as 25%, 40%, 55%, 70%, 85% or any value between any intervals of the above values.
[0052] In some embodiments, the microparticles can be loaded into capsules, aluminum foil blister, and drug storage tank in a dry powder inhaler device for inhalation by an individual in need thereof.
[0053] In some embodiments, method 100 further comprises mixing the microparticles with a second pharmaceutically acceptable excipient different from the first pharmaceutically acceptable excipient. It is worth noting that the addition of the second pharmaceutically acceptable excipient improves the aerosol properties, extends the flight distance of the microparticles, and increases the distribution ratio of the microparticles in the lungs after inhalation administration.
[0054] In some embodiments, the second pharmaceutically acceptable excipient comprises lactose, mannitol, or a combination thereof.
[0055] In some embodiments, the second pharmaceutically acceptable excipient includes a first size group, a second size group, or a combination thereof, wherein the volume-based particle size distribution of the first size group is different from the volume-based particle size distribution of the second size group. In some embodiments, the D50 particle size of the first size group is 5 microns to 50 microns (5 microns, 10 microns, 20 microns, 30 microns, 40 microns, 50 microns, or any value between any intervals of the above values), and the D50 particle size of the second size group is 30 microns to 125 microns (30 microns, 40 microns, 50 microns, 60 microns, 70 microns, 80 microns, 90 microns, 100 microns, 110 microns, 125 microns, or any value between any intervals of the above values).
[0056] In some embodiments, the weight ratio of the second pharmaceutically acceptable excipient to the microparticle is 70:30 to 99.995:0.005, such as 70:30, 80:20, 90:10, 99.995:0.005, or any value between any intervals of the above values. If the weight ratio of the second pharmaceutically acceptable excipient is too high, the active ingredient that can be provided by a specific unit of the pharmaceutical composition is limited. If the weight ratio of the second pharmaceutically acceptable excipient is too low, the improvement of the aerosol properties is limited.
[0057] In some embodiments, method 100 further comprises mixing the microparticles with a flavoring agent (eg, menthol or a natural flavoring agent such as lemon, strawberry, orange, etc.), wherein the flavoring agent is present in an amount of less than 1% by weight to reduce the bitter taste during inhalation.
[0058] In some embodiments, a dry powder inhalation pharmaceutical composition is provided, comprising: an active ingredient and a first pharmaceutically acceptable excipient. The active ingredient comprises bedaquiline or a pharmaceutically acceptable salt thereof. The first pharmaceutically acceptable excipient comprises an amino acid, a polysaccharide, a phospholipid, polylactic acid, a polylactic acid copolymer, or a combination thereof.
[0059] By using the first pharmaceutically acceptable excipient, the shape and particle size of the spray-dried pharmaceutical composition can be controlled to improve the aerosol properties of the pharmaceutical composition.
[0060] In some embodiments, the viscosity of the first pharmaceutically acceptable excipient is less than 3 dL / g, for example, 0.1 dL / g to 3 dL / g. If the viscosity is too high, the first pharmaceutically acceptable excipient is difficult to spray dry, and the particle size of the microparticles is too large to meet the requirements of inhalation administration.
[0061] In some embodiments, when the weight of the active ingredient and the first pharmaceutically acceptable excipient is 100%, the weight percentage of the active ingredient is 50% to 99% (e.g., 50%, 60%, 70%, 80%, 90%, 95%, 99% or any value between any intervals of the above values), and the weight percentage of the first pharmaceutically acceptable excipient is 1% to 50% (e.g., 1%, 10%, 20%, 30%, 40%, 50% or any value between any intervals of the above values). If the weight percentage of the active ingredient is too low or the weight percentage of the first pharmaceutically acceptable excipient is too high, the active ingredient that can be provided by a specific unit of the pharmaceutical composition is limited. If the weight percentage of the active ingredient is too high or the weight percentage of the first pharmaceutically acceptable excipient is too low, the aerosol properties of the pharmaceutical composition are weakened.
[0062] In some embodiments, when the weight of the active ingredient and the first pharmaceutically acceptable excipient is 100%, the weight percentage of the amino acid is 1% to 20% (e.g., 1%, 5%, 10%, 15%, 20% or any value between any intervals of the above values). If the weight percentage of the amino acid is too high, the active ingredient that can be provided by a specific unit of the pharmaceutical composition is limited. If the weight percentage of the amino acid is too low, the aerosol properties of the pharmaceutical composition are weakened.
[0063] In some embodiments, when the weight of the active ingredient and the first pharmaceutically acceptable excipient is 100%, the weight percentage of the polysaccharide is 1% to 20% (e.g., 1%, 5%, 10%, 15%, 20%, or any value between any intervals of the above values). If the weight percentage of the polysaccharide is too high, the active ingredient that can be provided by a specific unit of the pharmaceutical composition is limited. If the weight percentage of the polysaccharide is too low, the aerosol property of the pharmaceutical composition is weakened.
[0064] In some embodiments, when the weight of the active ingredient and the first pharmaceutically acceptable excipient is 100%, the weight percentage of the phospholipid is 1% to 50% (e.g., 1%, 5%, 10%, 15%, 20%, 30%, 40%, 50% or any value between any intervals of the above values). If the weight percentage of the phospholipid is too high, the active ingredient that can be provided by a specific unit of the pharmaceutical composition is limited. If the weight percentage of the phospholipid is too low, the aerosol properties of the pharmaceutical composition are weakened.
[0065] In some embodiments, when the weight of the active ingredient and the first pharmaceutically acceptable excipient is 100%, the weight percentage of polylactic acid (PLA) is 1% to 50% (e.g., 1%, 5%, 10%, 15%, 20%, 30%, 40%, 50% or any value between any intervals of the above values). If the weight percentage of PLA is too high, the active ingredient that can be provided by a specific unit of the pharmaceutical composition is limited. If the weight percentage of PLA is too low, the aerosol properties of the pharmaceutical composition are weakened.
[0066] In some embodiments, when the weight of the active ingredient and the first pharmaceutically acceptable excipient is 100%, the weight percentage of the polylactic acid copolymer (e.g., PLGA) is 1% to 50% (e.g., 1%, 5%, 10%, 15%, 20%, 30%, 40%, 50% or any value between any intervals of the above values). If the weight percentage of the polylactic acid copolymer is too high, the active ingredient that can be provided by a specific unit of the pharmaceutical composition is limited. If the weight percentage of the polylactic acid copolymer is too low, the aerosol properties of the pharmaceutical composition are weakened.
[0067] In some embodiments, the active ingredient and the first pharmaceutically acceptable excipient form microparticles having a particle size of 50 nanometers to 6 micrometers, such as 50 nanometers, 100 nanometers, 500 nanometers, 1 micrometer, 2 micrometers, 3 micrometers, 4 micrometers, 5 micrometers, 6 micrometers, or any value between any intervals of the above values. It is worth noting that the particle size of the microparticles is smaller than the active ingredient that has not been spray-dried. Therefore, the particle size requirement for inhalation into the lungs is met.
[0068] In some embodiments, the microparticles are in the shape of solid spheres, hollow spheres, solid polyhedrons, or a combination thereof. The shapes of these microparticles can increase the flight distance of the microparticles and increase the distribution ratio of the microparticles in the lungs when administered.
[0069] In some embodiments, the pharmaceutical composition further comprises a second pharmaceutically acceptable excipient different from the first pharmaceutically acceptable excipient, such as lactose, mannitol, or a combination thereof. The addition of the second pharmaceutically acceptable excipient can further increase the flight distance of the microparticles and increase the distribution ratio of the microparticles in the lungs when administered.
[0070] In some embodiments, when the weight of the pharmaceutical composition is 100%, the weight percentage of the second pharmaceutically acceptable excipient is 70% to 99.995%, such as 70%, 80%, 90%, 95%, 99.995% or any value between any intervals of the above values. If the weight percentage of the second pharmaceutically acceptable excipient is too high, the active ingredient that can be provided by a specific unit of the pharmaceutical composition is limited. If the weight percentage of the second pharmaceutically acceptable excipient is too low, the aerosol properties of the pharmaceutical composition are weakened.
[0071] In some embodiments, the pharmaceutical composition further comprises a third pharmaceutically acceptable excipient for modulating specific properties, such as modulating aerodynamics or taste.
[0072] It should be understood that the above-mentioned embodiments and the following examples are provided for illustration rather than limitation. According to the description, it is clear to those skilled in the art that various changes and modifications can be made within the scope of the present disclosure.
[0073] In order to clarify the dry powder inhalation pharmaceutical composition and its preparation method, several examples and efficacy tests are provided in sequence below.
[0074] Example 1 - Preparation method and physical properties of dry powder inhalation pharmaceutical composition
[0075] The first pharmaceutically acceptable excipient added before spray drying
[0076] Amino Acids
[0077] Step a: Bedaquiline and leucine are dissolved in ethanol respectively, and then the two are mixed with each other according to the formula in Table 1.
[0078] Table 1
[0079]
[0080] Step b: spray drying the mixed solution obtained in step a at an outlet temperature of 80° C. and an atomization ratio of 65% to form microparticles.
[0081] Compared with other conditions in Table 1, the microparticles prepared by a weight ratio of 95:5 and a concentration of 1.0% achieved better mixing and spray drying effects, and were selected for subsequent physical property observations.
[0082] The shape of particles
[0083] The appearance of bedaquiline in different preparation steps was observed under an electron microscope. The results are shown in Figure 2A as well as Figure 2B ,in Figure 2A Bedaquiline in the step is observed before step b (without spray drying), Figure 2B Bedaquiline in is observed after step b (spray drying).
[0084] Figure 2A The bedaquiline before step b (without spray drying) is irregular and fragmented in shape. Figure 2B The microparticle shape (after spray drying) is spherical.
[0085] Particle size
[0086] After 5 repeated tests, the particle sizes (D10, D50, and D90) of the microparticles were analyzed and the results are summarized in Table 2.
[0087] Table 2
[0088]
[0089] Note: D10 refers to the particle size corresponding to 10% cumulative frequency. D50 refers to the particle size corresponding to 50% cumulative frequency. D90 refers to the particle size corresponding to 90% cumulative frequency.
[0090] It can be observed during the process that the particle size of the microparticles is less than 2 μm, which is smaller than bedaquiline that has not been spray dried (not shown in Table 2).
[0091] Phospholipids
[0092] Step a: Bedaquiline and DPPC (molecular weight (Mw) = 744 g / mol), bedaquiline and DPSC (Mw = 790 g / mol) were dissolved in ethanol respectively, and then the two were mixed with each other according to the formula of Table 3.
[0093] Table 3
[0094]
[0095] Step b: spray drying the mixed solution obtained in step a at an outlet temperature of 80° C. and an atomization ratio of 65% to form microparticles.
[0096] Compared with other conditions in Table 3, the microparticles prepared by the weight ratio of 99:1 and the concentration of 2% have a smaller particle size and a more spherical shape, and are selected for subsequent physical property observations.
[0097] The shape of particles
[0098] The appearance of bedaquiline after spray drying (DPPC or DPSC as the first pharmaceutically acceptable excipient) was observed under an electron microscope. The results are shown in Figure 3A as well as Figure 3B . Figure 3A as well as Figure 3B In the form of particles, Figure 3A The bedaquiline was mixed with DPPC before spray drying. Figure 3B The bedaquiline was mixed with DSPC before spray drying.
[0099] Figure 3A as well as Figure 3B It is shown that the shape of the microparticles is spherical or polyhedral (eg, golf ball-shaped, ie, a solid polyhedron with a plurality of grooves on the surface).
[0100] Particle size
[0101] The particle sizes (D10, D50, and D90) of the microparticles obtained by mixing bedaquiline and DPPC were analyzed through 5 repeated tests, and the results are summarized in Table 4.
[0102] Table 4 (addition of DPPC)
[0103]
[0104] Table 5 summarizes the particle sizes (D10, D50, and D90) of the microparticles obtained by mixing bedaquiline and DSPC.
[0105] Table 5 (Add DSPC)
[0106]
[0107] It can be observed during the process that the particle size of the microparticles is less than 5 μm, which is smaller than bedaquiline that has not been spray-dried (not shown in Tables 4 and 5).
[0108] Polylactic acid or polylactic acid copolymer
[0109] Step a: Bedaquiline and polylactic-glycolic acid (PLGA) having a viscosity of 0.16 dL / g to 0.24 dL / g were dissolved in ethanol respectively, and then the two were mixed with each other according to the formulation of Table 6.
[0110] Table 6
[0111]
[0112] Step b: spray drying the mixed solution obtained in step a at an outlet temperature of 45° C. and an atomization ratio of 65% to form microparticles.
[0113] Compared to the other conditions in Table 6, the microparticles prepared by the weight ratio of 95:1 and the concentration of 2.0% have a smaller particle size and a more spherical shape, and are selected for subsequent physical property observations.
[0114] The shape of particles
[0115] The appearance of the microparticles was observed under an electron microscope (PLGA was used as the first pharmaceutically acceptable excipient). Figure 4 .
[0116] Figure 4 The shape of the microparticles is spherical or polyhedral (eg, golf ball shape).
[0117] Particle size
[0118] After 5 repeated tests, the particle sizes (D10, D50, and D90) of the microparticles were analyzed, and the results are summarized in Table 7.
[0119] Table 7
[0120]
[0121] It can be observed during the process that the particle size of the microparticles is less than 5.5 μm, which is smaller than bedaquiline that has not been spray dried (not shown in Table 7).
[0122] A second pharmaceutically acceptable excipient added after spray drying
[0123] Lactose or mannitol
[0124] Lactose or mannitol with two particle sizes is added to a high-efficiency mixer and mixed with the microparticles obtained in point 1. (2). The microparticles use DPSC as the first pharmaceutically acceptable excipient, and the weight ratio and concentration are selected to be 99:1 and 2%. The mixing ratio of the second pharmaceutically acceptable excipient (lactose or mannitol) and bedaquiline is obtained according to Table 8 (lactose) or Table 9 (mannitol).
[0125] Table 8
[0126]
[0127] Table 9
[0128]
[0129] Aerosol properties
[0130] In order to compare the aerosol properties of microparticles prepared by direct spray drying, adding the first pharmaceutically acceptable excipient before spray drying, or adding the first pharmaceutically acceptable excipient before spray drying and adding the second pharmaceutically acceptable excipient after spray drying, microparticles of the "BED only" group, the "BED+DSPC" group, and the "BED+DSPC+Lac" group were provided for detecting aerosol properties, and the aerosol properties were detected according to the Next Generation Impactor (NGI) (brand: Copley Scientific, equipment name: Model 170) in a cascade impaction (CI) at an airflow rate of 60 liters / minute. The "BED only" group was prepared by direct spray drying of bedaquiline, the "BED+DSPC" group was prepared by adding the first pharmaceutically acceptable excipient (DSPC) before spray drying, and the "BED+DSPC+Lac" group was prepared by adding the first pharmaceutically acceptable excipient (DSPC) before spray drying and the second pharmaceutically acceptable excipient (lactose) after spray drying.
[0131] Please refer to the results Figure 5 And Table 10 (data compiled from Figure 5 ), the fine particle fraction (FPF) is the percentage of the cumulative deposition content of particles smaller than 5 microns to the total output particle content, reflecting the effective deposition rate of particles in the lungs.
[0132] Figure 5It is shown that, compared with the "BED only" group, the particles of the "BED+DSPC" group and the "BED+DSPC+Lac" group are less distributed in the induction port (IP) stage and the preseparator (Preseparator) stage (relatively short flight distance), while the particles of the "BED+DSPC" group and the "BED+DSPC+Lac" group are distributed more in the subsequent stages, such as the S2 stage to the S8 stage, indicating that a relatively long flight distance can be achieved. That is, compared with the "BED only" group, the "BED+DSPC" group and the "BED+DSPC+Lac" group have a longer flight distance.
[0133] In addition, compared with the "BED+DSPC" group, it can be observed that the distribution of the particles in the "BED+DSPC+Lac" group is improved in the S3 to S6 order (which requires a relatively long flight distance). That is, compared with the "BED+DSPC" group, the "BED+DSPC+Lac" group further exhibited a longer flight distance.
[0134] Table 10
[0135]
[0136] Note: MMAD is the mass median aerodynamic diameter.
[0137] Table 10 shows that the "BED+DSPC" group and the "BED+DSPC+Lac" group showed higher FPF and smaller MMAD compared with the "BED only" group; the "BED+DSPC+Lac" group showed higher FPF and smaller MMAD compared with the "BED+DSPC" group.
[0138] therefore, Figure 5 And Table 10 reveals that the flight distances in these three groups are ranked (long to short) in the order of (1) microparticles prepared by adding the first pharmaceutically acceptable excipient before spray drying and adding the second pharmaceutically acceptable excipient after spray drying, (2) microparticles prepared by adding the first pharmaceutically acceptable excipient before spray drying, and (3) microparticles prepared by directly spray drying bedaquiline. That is, according to the above data, compared with microparticles prepared by direct spray drying, microparticles prepared by adding the first pharmaceutically acceptable excipient, or microparticles prepared by adding the first pharmaceutically acceptable excipient and the second pharmaceutically acceptable excipient, achieve a higher distribution ratio in the lung.
[0139] Next, please return to Figure 2B , Figure 3A , Figure 3B as well as Figure 4 , and together Figure 5 As well as Table 10, it should also be emphasized that when bedaquiline is mixed with a first pharmaceutically acceptable excipient at least before spray drying, the shape of the resulting microparticles can achieve a longer flight distance and a higher distribution ratio of the microparticles in the lungs when administered.
[0140] Example 2 - Animal Experiment for Comparative Test
[0141] In order to observe the absorption efficiency, Sprague-Dawley rats (SD rats) were selected as experimental animals, and the grouping of the animal experiments was obtained according to Table 11, wherein the microparticles of the "BED+Leu" group were obtained from point 1(1) of Example 1 (weight ratio of 95:5 and concentration of 1.0%), and the microparticles of the "BED+DSPC" group were obtained from point 1(2) of Example 1 (weight ratio of 99:1 and concentration of 2%).
[0142] Table 11
[0143]
[0144] Blood samples of 0.2 ml / rat to 0.3 ml / rat were collected from the submandibular vein or anterior vena cava of rats in Groups 1 and 2 before administration and 2 minutes, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 10 hours, 24 hours, and 48 hours after administration. Blood samples of Group 3 were collected before administration and 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 10 hours, 24 hours, and 48 hours after administration in a similar collection method to Groups 1 and 2. The blood samples of each group were mixed with heparin sodium for anticoagulation (at least 40 U of heparin sodium to anticoagulate 1 ml of blood). The anticoagulated blood was then centrifuged at 2000 g for 10 minutes at 4°C to collect the centrifuged plasma, which was then transferred to a new tube for analysis or stored at -30°C until analysis.
[0145] Next, the pharmacokinetic parameters of bedaquiline in the three groups were analyzed via blood samples and summarized in Table 12.
[0146] Table 12
[0147]
[0148] Note: T1 / 2 is the half-life of bedaquiline in the blood, Cmax is the maximum plasma concentration, and Tmax is the time to reach Cmax.
[0149] Table 12 shows that Group 1 and Group 2 have shorter Tmax (about 5 minutes) than Group 3, indicating that less time is required to reach Cmax. That is, the onset time of Group 1 and Group 2 (inhalation) is faster than that of Group 3 (oral administration).
[0150] Although the present disclosure has been described in detail with respect to certain embodiments, other embodiments are possible. Therefore, the spirit and scope of the appended claims should not be limited to the embodiments described herein.
[0151]
Explanation of symbols
[0152] 100: Methods
[0153] S110, S120, S130, S140: steps.
Claims
1. A dry powder inhalation pharmaceutical composition, characterized in that: include: An active ingredient, wherein the active ingredient comprises bedaquiline or a pharmaceutically acceptable salt thereof; as well as The first pharmaceutically acceptable excipient includes amino acids, polysaccharides, phospholipids, polylactic acid, polylactic acid copolymers or a combination thereof.
2. The pharmaceutical composition according to claim 1, wherein when the weight of the active ingredient and the first pharmaceutically acceptable excipient is 100%, the weight percentage of the active ingredient is 50% to 99%, and the weight percentage of the first pharmaceutically acceptable excipient is 1% to 50%.
3. The pharmaceutical composition according to claim 1, wherein when the weight of the active ingredient and the first pharmaceutically acceptable excipient is 100%, the weight percentage of the amino acid is 1% to 20%.
4. The pharmaceutical composition of claim 1, wherein the amino acid comprises glycine, alanine, valine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, histidine, asparagine, glutamic acid, lysine, glutamine, methionine, arginine, serine, threonine, cysteine, proline, or a combination thereof.
5. The pharmaceutical composition according to claim 1, wherein when the weight of the active ingredient and the first pharmaceutically acceptable excipient is calculated as 100%, the weight percentage of the polysaccharide is 1% to 20%.
6. The pharmaceutical composition according to claim 1, wherein the polysaccharide comprises chitosan, chitosan salt or a combination thereof.
7. The pharmaceutical composition according to claim 1, wherein when the weight of the active ingredient and the first pharmaceutically acceptable excipient is calculated as 100%, the weight percentage of the phospholipid is 1% to 50%.
8. The pharmaceutical composition according to claim 1, wherein the phospholipid comprises dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine or a combination thereof.
9. The pharmaceutical composition according to claim 1, wherein when the weight of the active ingredient and the first pharmaceutically acceptable excipient is 100%, the weight percentage of the polylactic acid is 1% to 50%.
10. The pharmaceutical composition according to claim 1, wherein when the weight of the active ingredient and the first pharmaceutically acceptable excipient is calculated as 100%, the weight percentage of the polylactic acid copolymer is 1% to 50%. The pharmaceutical composition according to claim 1 , wherein the polylactic acid copolymer comprises polylactic acid-glycolic acid.
12. The pharmaceutical composition according to claim 1, wherein the active ingredient and the first pharmaceutically acceptable excipient form microparticles with a particle size of 50 nanometers to 6 micrometers.
13. The pharmaceutical composition according to claim 12, wherein the microparticles are in the shape of solid spheres, hollow spheres, solid polyhedrons or a combination thereof.
14. The pharmaceutical composition according to claim 1, wherein Also included is a second pharmaceutically acceptable excipient that is different from the first pharmaceutically acceptable excipient.
15. The pharmaceutical composition according to claim 14, wherein when the weight of the pharmaceutical composition is 100%, the weight percentage of the second pharmaceutically acceptable excipient is 70% to 99.995%.
16. The pharmaceutical composition of claim 14, wherein the second pharmaceutically acceptable excipient comprises lactose, mannitol or a combination thereof.
17. A method for preparing a dry powder inhalation pharmaceutical composition, characterized in that: include: dissolving an active ingredient in a first solvent to form a first solution, wherein the active ingredient comprises bedaquiline or a pharmaceutically acceptable salt thereof; Dissolving a first pharmaceutically acceptable excipient in a second solvent to form a second solution, wherein the first pharmaceutically acceptable excipient comprises amino acids, polysaccharides, phospholipids, polylactic acid, polylactic acid copolymers or a combination thereof; mixing the first solution and the second solution to form a mixed solution; and The mixture is spray dried to form microparticles.
18. The method of claim 17, wherein the first solvent and the second solvent comprise organic solvents.
19. The method according to claim 17, wherein when the weight of the mixed solution is 100%, the weight percentage of the active ingredient and the first pharmaceutically acceptable excipient is 0.5% to 3%.
20. The method according to claim 17, wherein the weight ratio of the active ingredient to the first pharmaceutically acceptable excipient in the mixed solution is 1:1 to 199:
1.
21. The method according to claim 17, wherein spray drying the mixed solution is performed at an outlet temperature of 35°C to 110°C.
22. The method according to claim 17, wherein in the step of spray drying the mixed solution, the ultrasonic atomization percentage of the mixed solution is 25% to 85%.
23. The method according to claim 17, wherein: Also included is mixing the microparticles with a second pharmaceutically acceptable excipient that is different from the first pharmaceutically acceptable excipient.
24. The method of claim 23, wherein the second pharmaceutically acceptable excipient comprises a first size group, a second size group, or a combination thereof, wherein the volume-based particle size distribution of the first size group is different from the volume-based particle size distribution of the second size group.
25. The method of claim 24, wherein the D50 particle size of the first size group is 5 microns to 50 microns, and the D50 particle size of the second size group is 30 microns to 125 microns.
26. The method of claim 17, wherein: Also included is mixing the microparticles with a flavoring agent.
